Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population ages

Introduction

In 2010, Datamonitor estimates that there were 92.4 million prevalent cases of benign prostatic hyperplasia (BPH) in men over age 50 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK); approximately 49% of these cases were symptomatic. The largest number of cases (28.4 million) was in the US.

Features and benefits

* Gain insight into market potential, including a robust 10-year epidemiology forecast of total and symptomatic prevalent cases of BPH.
* Understand the key epidemiologic risk factors associated with benign prostatic hyperplasia.

Highlights

Datamonitor expects to see an increase in the number of histologic benign prostatic hyperplasia (BPH) cases between 2010 and 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). The number of total BPH cases is expected to increase from approximately 79.1 million cases in 2010 to 92.4 million cases in 2020.
Datamonitor expects to see an increase in the number of symptomatic benign prostatic hyperplasia (BPH) cases between 2010 and 2020 in the seven major markets. The number of symptomatic BPH cases is expected to increase from around 38.9 million cases in 2010 to 45.8 million cases in 2020.
The largest increase in the number of BPH cases is expected in the US for both total and symptomatic BPH. Between 2010 and 2020, the number of total prevalent cases of BPH will increase by 2.2% annually and the number of symptomatic BPH cases will increase by 2.4% annually.

Your key questions answered

* What are the most robust sources for benign prostatic hyperplasia prevalence data?
* How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
* How do changes in population structure and risk factors affect the trend in prevalent benign prostatic hyperplasia cases?
[Studien Infos ausblenden]

Executive Summary
Epidemiology of benign prostatic hyperplasia
Benign prostatic hyperplasia in the seven major markets
Datamonitor’s forecast of benign prostatic hyperplasia
OVERVIEW
Catalyst
Summary
DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
Diagnosis definition and diagnosis of benign prostatic hyperplasia
Definition of benign prostatic hyperplasia
GLOBAL VARIATION AND HISTORICAL TRENDS
Global variation and historical trends in prevalence
The greatest variation in benign prostatic hyperplasia is in symptomatic prevalence, not total prevalence
Mortality trends
Mortality from benign prostatic hyperplasia has decreased significantly in the last 60 years
DRIVERS OF BENIGN PROSTATIC HYPERPLASIA EPIDEMIOLOGY
Age and genetics are the most significant risk factors, with controversy surrounding many other risk factors
Age is the most important risk factor for benign prostatic hyperplasia
There is a significant genetic link in the development of BPH
Some lifestyle factors may have an association with increased risk of benign prostatic hyperplasia
Some studied factors have shown conflicting results or no association with increased risk of benign prostatic hyperplasia
Some lifestyle factors have been found to protect against benign prostatic hyperplasia
Physical activity and moderate alcohol intake have been shown to reduce the risk of benign prostatic hyperplasia
Diseases with high prevalence rates in the elderly are often co-morbid with benign prostatic hyperplasia
Cardiovascular disease risk factors are highly co-morbid with benign prostate hyperplasia
Type 2 diabetes mellitus is co-morbid with benign prostatic hyperplasia, both common in the elderly
Sexual dysfunction is a common co-morbidity of benign prostatic hyperplasia
EPIDEMIOLOGIC FORECASTING OF BENIGN PROSTATIC HYPERPLASIA
Overview
Subpopulations
Age
Total prevalence of benign prostatic hyperplasia
Sources used
Methods
Symptomatic prevalence of benign prostatic hyperplasia
US
Japan
France
Germany
Italy
Spain
UK
EPIDEMIOLOGIC RESULTS
Total prevalent histologic cases and future trends
Total prevalent cases of histologic BPH by age group
Symptomatic prevalent cases and future trends
Symptomatic benign prostatic hyperplasia by age group
Age-standardized prevalence rates
DISCUSSION
Strengths and limits of Datamonitor’s epidemiologic projections
Conclusions
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Module methodology
[Inhaltsverzeichnis ausblenden]